Mobia Medical (NASDAQ:MOBI) Director Buys 16,441 Shares

Mobia Medical, Inc. (NASDAQ:MOBI) Director Casey Tansey purchased 16,441 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The shares were purchased at an average cost of $12.07 per share, with a total value of $198,442.87. Following the completion of the purchase, the director owned 318,332 shares of the company’s stock, valued at $3,842,267.24. The trade was a 5.45% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

Mobia Medical Stock Performance

NASDAQ:MOBI traded down $0.47 during trading hours on Thursday, reaching $10.95. The stock had a trading volume of 71,930 shares, compared to its average volume of 103,512. The company has a market capitalization of $364.53 million and a PE ratio of -0.57. Mobia Medical, Inc. has a 52 week low of $10.19 and a 52 week high of $15.29. The company’s 50 day moving average price is $12.35. The company has a debt-to-equity ratio of 0.04, a current ratio of 13.28 and a quick ratio of 12.80.

Mobia Medical (NASDAQ:MOBI) last posted its earnings results on Tuesday, August 11th. The company reported ($1.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.27). The firm had revenue of $13.51 million during the quarter. The company’s quarterly revenue was up 102.4% on a year-over-year basis. Equities research analysts predict that Mobia Medical, Inc. will post -2.76 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have commented on MOBI shares. Zacks Research upgraded shares of Mobia Medical to a “hold” rating in a research report on Wednesday, June 3rd. Wolfe Research assumed coverage on shares of Mobia Medical in a research report on Tuesday, June 2nd. They set an “outperform” rating on the stock. JPMorgan Chase & Co. upped their target price on shares of Mobia Medical from $15.00 to $17.00 and gave the company an “overweight” rating in a research report on Wednesday, August 12th. The Goldman Sachs Group began coverage on shares of Mobia Medical in a report on Tuesday, June 2nd. They issued a “buy” rating and a $31.00 price target for the company. Finally, Bank of America assumed coverage on Mobia Medical in a research report on Tuesday, June 2nd. They issued a “buy” rating and a $16.00 price target for the company. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $20.75.

Mobia Medical Company Profile

Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc is based in AUSTIN, Texas.